Keyphrases
Aptamer
56%
Binding Affinity
33%
Combination Chemotherapy
30%
Triple-negative Breast Cancer
30%
Paclitaxel
30%
Bone Anabolic Effects
30%
Cancer Therapy
30%
Controlled Drug Release
30%
Targeted Combination
30%
Small Interfering RNA (siRNA)
30%
In Cancer
30%
Therapeutic Use
30%
Nucleolin Aptamer
30%
Sclerostin
30%
Quinoline
30%
Modified Aptamers
30%
Fluorouracil
26%
Targeted Delivery
15%
Tumorigenesis
12%
Therapeutic Agents
12%
Chemical Modification
12%
Triple-negative Breast Cancer Cells
11%
AS1411
11%
Thioether
11%
Linker
11%
Modification Strategies
10%
Precision Medicine
9%
Osteogenesis Imperfecta
8%
Bone Formation
8%
Molecular Recognition
8%
Inhibitory Effect
7%
Breast Cancer Progression
7%
Storage Life
6%
Prolonged Storage
6%
Success Probability
6%
Oligonucleotide Sequence
6%
Low Immunogenicity
6%
Delivery Material
6%
Improved Patient Outcomes
6%
Ocular Diseases
6%
Aptamer-drug Conjugates (ApDCs)
6%
Batch-to-batch
6%
Gene Therapy
6%
Target Molecule
6%
Oncologic
6%
Gene Regulation
6%
Liver
6%
Monoclonal Antibody
6%
Metabolic Disease
6%
Treatment Strategy
6%
Molecular Mechanism
6%
Multi-omics Integration
6%
High Performance
6%
Cancer Treatment
6%
Clinical Translation
6%
Antisense Oligonucleotides
6%
Gene Inhibition
6%
Tumor Development
6%
Neuromuscular Disease
6%
Plethora
6%
Remaining Challenges
6%
MicroRNA
6%
Pharmacology, Toxicology and Pharmaceutical Science
Aptamer
100%
Triple Negative Breast Cancer
30%
Chemotherapy
30%
Sclerostin
30%
Nucleolin
30%
Controlled Drug Release
30%
Malignant Neoplasm
30%
Paclitaxel
21%
Carcinogenesis
20%
Diseases
20%
Fluorouracil
19%
Neoplasm
15%
Eye Disease
9%
Clinical Study
9%
Preclinical Study
9%
Tamsulosin
9%
microRNA
9%
Antisense Oligonucleotide
9%
Small Interfering RNA
9%
Neuromuscular Disease
9%
Thioether
8%
Oligonucleotide
7%
Immunogenicity
7%
Osteogenesis Imperfecta
7%
Cancer Growth
5%
Drug Conjugate
5%
Monoclonal Antibody
5%
Medicine and Dentistry
Aptamer
39%
Cancer Therapy
30%
Carcinogenesis
20%
Therapeutic Agent
15%
Neoplasm
9%
microRNA
9%
Personalized Medicine
9%
Antisense Oligonucleotide
9%
Small Interfering RNA
9%
Diseases
9%
Tamsulosin
9%
Gene Expression
9%
Eye Disease
9%
Play Therapy
9%
Metabolic Liver Disease
9%
Neuromuscular Disease
9%
Immunogenicity
5%
Health Care Cost
5%
Drug Conjugate
5%
Nucleotide Sequence
5%
Monoclonal Antibody
5%